Stem Cell Therapy Shows Promise for Severe Knee Osteoarthritis in 140-Patient Study
Adipose-derived stem cells combined with platelet-rich plasma evaluated for treating moderate to severe knee osteoarthritis over 2 years.
Summary
Researchers investigated whether stem cells extracted from patients' own fat tissue could help treat severe knee osteoarthritis. The completed study followed 140 patients with advanced knee arthritis for two years after receiving injections of their own adipose-derived stem cells combined with platelet-rich plasma. Participants had stage 3 and 4 osteoarthritis, representing moderate to severe joint damage. The treatment aimed to regenerate cartilage rather than just manage pain like traditional therapies. Researchers measured improvements using pain and function scores, walking ability, medication needs, and imaging studies of cartilage thickness and joint space.
Detailed Summary
This completed clinical trial evaluated whether stem cell therapy could offer a regenerative solution for severe knee osteoarthritis, moving beyond traditional pain management approaches. The study investigated autologous adipose-derived stromal cells combined with platelet-rich plasma as a potential cartilage-regenerating treatment.
Researchers enrolled 140 patients with moderate to severe knee osteoarthritis, specifically stages 3 and 4, representing advanced joint degeneration. Each participant received injections of stem cells harvested from their own adipose tissue, combined with platelet-rich plasma to potentially enhance healing effects.
The comprehensive two-year follow-up protocol included multiple assessment methods. Researchers tracked subjective improvements using WOMAC scores for pain and function, measured walking capacity through six-minute walking distance tests, and monitored patients' need for rescue medications. Objective measures included radiographic evaluation of joint space and MRI assessment of cartilage thickness changes.
This approach represents a significant shift from conventional osteoarthritis treatment, which typically focuses on symptom management rather than tissue regeneration. Mesenchymal stem cells from adipose tissue offer potential advantages including easier harvesting compared to bone marrow sources and robust regenerative capabilities.
The study's completion provides valuable data on stem cell therapy's safety and efficacy for advanced osteoarthritis. Given the aging population and increasing prevalence of joint degeneration, regenerative treatments could significantly impact quality of life and mobility preservation. The two-year follow-up period offers meaningful insights into treatment durability, addressing whether benefits persist beyond initial improvements and potentially reducing long-term healthcare costs associated with chronic osteoarthritis management.
Key Findings
- 140 patients with severe knee osteoarthritis completed 2-year stem cell therapy evaluation
- Autologous fat-derived stem cells combined with platelet-rich plasma were tested
- Multiple outcome measures included pain scores, walking ability, and cartilage imaging
- Study focused on regenerative treatment rather than traditional pain management approaches
Methodology
This was an observational study enrolling 140 participants with stage 3-4 knee osteoarthritis. The trial ran for approximately 5 years with 2-year patient follow-up periods. No control group information was provided in the available summary.
Study Limitations
The trial summary lacks control group details and specific outcome results. Generalizability may be limited to patients with advanced osteoarthritis stages. Long-term safety and efficacy beyond two years remains unclear.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.